2,4-二硝基苯酚(1-) | 20350-26-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2,4-二硝基苯酚(1-)
• 英文名称: 2,4-dinitrophenolate
• 英文别名: 2,4-dinitrophenoxide；2,4-dinitrophenoxide anion；2,4-dinitrophenoxide ion；DNP
• CAS: 20350-26-9
• 化学式: C₆H₃N₂O₅
• 分子量: 183.1
• InChiKey: UFBJCMHMOXMLKC-UHFFFAOYSA-M

物化性质

• 熔点：
  75 °C (decomp)

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  13
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  115
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  2,4-二硝基苯酚(1-) 在 sodium tetrahydroborate 作用下， 以 水 为溶剂， 生成
  参考文献：
  名称：

  摘要：

  Initial F-420-dependent hydrogenation of 2,4,6-trinitrophenol (picric acid) generated the hydride sigma-complex of picrate and finally the dihydride complex. With 2,4-dinitrophenol the hydride sigma-complex of 2,4-dinitrophenol is generated. The hydride transferring enzyme system showed activity against several substituted 2,4-dinitrophenols but not with mononitrophenols. A K-m-value of 0.06 mM of the hydride transfer for picrate as substrate was found. The pH optima of the NADPH-dependent F-420 reductase and for the hydride transferase were 5.5 and 7.5, respectively. An enzymatic activity has been identified catalyzing the release of stoichometric amounts of I mol nitrite from 1 mol of the dihydride sigma-complex of picrate. This complex was synthesized by chemical reduction of picrate and characterized by H-1 and C-13 NMR spectroscopy. The hydride sigma-complex of 2,4-dinitrophenol has been identified as the denitration product. The nitrite-eliminating activity was enriched and clearly separated from the hydride transferring enzyme system by FPLC. 2,4-Dinitrophenol has been disproven as a metabolite of picrate (Ebert et al. 1999) and a convergent catabolic pathway for picrate and 2,4-dinitrophenol with the hydride sigma-complex of 2,4-dinitrophenol as the common intermediate has been demonstrated.

  DOI：

  10.1023/a:1014447700775
• 作为产物：
  描述：

  2,4-二硝基酚 在 三乙胺 、 sodium hydroxide 作用下， 以 乙醚 、 水 、 二甲基亚砜 、 乙腈 为溶剂， 生成 2,4-二硝基苯酚(1-)
  参考文献：
  名称：

  Y取代的苯基X取代的苯磺酸盐的碱水解动力学研究：亲核剂从叠氮化物变为氢氧根离子对反应性和过渡态结构的影响

  摘要：

  用分光光度法测量了2,4-二硝基苯基X-取代的苯磺酸盐（1a-1f）和Y-取代的苯基4-硝基苯磺酸盐（2a-2g）的碱解二级速率常数（）。比较与所述值之前为相应的反应报道显示，OH 只有10 3倍比更具反应性，虽然前者是11个P ķ 一个单位比后者更碱性。汤川-津野情节用于的反应中1A-1F导致具有优异的线性相关ρ X  = 2.09和- [R= 0.41。用于反应中的布朗斯台德型情节2A-2G是线性与β LG  = -0.51，这是典型的反应报告通过协调一致机理进行。汤川-津野情节用于的反应中2A-2G显示出优异的线性度ρ Ŷ  = 1.85和- [R = 0.25，这表明局部负电荷开发上离去基团的在过渡态O原子。因此，已得出结论认为1a-1f和2a-2g的碱性水解是通过协同机制进行的。所述的比较ρ X和β LG用于与反应值 离子表明，与氢氧根离子相比，与氢氧根离子的反应通过更紧密的过渡态结构进行。

  DOI：

  10.1002/bkcs.10297

文献信息

• Nucleophilic reactivity of thiolate, hydroxide, and phenolate ions toward a model<i>O</i>²-arylated diazeniumdiolate prodrug in aqueous and cationic surfactant media
  作者：Matthew S. Ning、Stacy E. Price、Jackie Ta、Keith M. Davies

  DOI：10.1002/poc.1607

  日期：——

  and in solutions of cationic DOTAP vesicles. Second-order rate constants in buffered aqueous solutions (k(RS(-) ) = 3.48 - 30.9 M(-1)s(-1); 30 degrees C) gave a linear Bronsted plot (beta(nuc) = 0.414 +/- 0.068) consistent with rate-limiting S(N)Ar nucleophilic attack by thiolate ions. Cationic DOTAP vesicles catalyze the thiolysis reactions with rate enhancements between 11 and 486-fold in Tris-HCl

  由前药DNP产生的一氧化氮被硫醇（L-谷胱甘肽，L-半胱氨酸，DL-高半胱氨酸，1-丙硫醇，2-巯基乙醇和硫代乙醇酸钠）一氧化氮芳族亲核取代的动力学。 -DEA / NO已在水溶液和阳离子DOTAP囊泡溶液中进行了检测。缓冲水溶液中的二阶速率常数（k（RS（-））= 3.48-30.9 M（-1）s（-1）; 30摄氏度）给出线性布朗斯泰德图（beta（nuc）= 0.414 + / -（0.068）与硫醇盐离子限制速率的S（N）Ar亲核攻击一致。阳离子DOTAP囊泡在pH 7.4的Tris-HCl缓冲溶液中催化硫解反应，速率提高11倍至486倍。巯基乙酸盐离子获得最大的速率增加。将硫解数据与酚盐（k（PhO（-））= 0.114 M（-1）s（-1））和氢氧化物（k（OH（-））= 1.82 x 10（-2）的亲核取代数据进行比较M（-1）s（-1），37摄氏度离子。CTAB胶束和DOD
• [EN] NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF DISEASES<br/>[FR] NOUVEAUX COMPOSÉS ET COMPOSITIONS PHARMACEUTIQUES ASSOCIÉES POUR LE TRAITEMENT DE MALADIES
  申请人：GALAPAGOS NV

  公开号：WO2020239658A1

  公开（公告）日：2020-12-03

  The present invention discloses compounds according to Formula (I), wherein R1a, R1b, R1c, R2a, W1, W2, X1, X2, X3, Y, and Z are as defined herein. The present invention relates to compounds, methods for their production, pharmaceutical compositions comprising the same, and methods of treatment using the same, for the prophylaxis and/or treatment of inflammatory diseases, autoinflammatory diseases, autoimmune diseases, proliferative diseases, fibrotic diseases, transplantation rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformation, diseases involving impairment of bone turnover, diseases associated with hypersecretion of IL-6, diseases associated with hypersecretion of TNFα, interferons, IL-12 and/or IL-23, respiratory diseases, endocrine and/or metabolic diseases, cardiovascular diseases, dermatological diseases, and/or abnormal angiogenesis associated diseases by administering the compound of the invention.

  本发明公开了根据式（I）的化合物，其中R1a、R1b、R1c、R2a、W1、W2、X1、X2、X3、Y和Z如本文所定义。本发明涉及化合物、其生产方法、包括其在内的制药组合物，以及使用这些化合物进行预防和/或治疗炎症性疾病、自身炎症性疾病、自身免疫性疾病、增生性疾病、纤维化疾病、移植排斥、涉及软骨周转障碍的疾病、先天软骨畸形、涉及骨周转障碍的疾病、与IL-6过度分泌有关的疾病、与TNFα、干扰素、IL-12和/或IL-23过度分泌有关的疾病、呼吸系统疾病、内分泌和/或代谢性疾病、心血管疾病、皮肤病和/或异常血管生成相关疾病的治疗方法，通过给予本发明的化合物。
• [EN] PROCESS FOR THE PREPARATION OF (Sp)-SOFOSBUVIR AND INTERMEDIATES THEREOF<br/>[FR] PROCÉDÉ DE PRÉPARATION DU (SP)-SOFOSBUVIR ET DE SES INTERMÉDIAIRES
  申请人：ALEMBIC PHARMACEUTICALS LTD

  公开号：WO2018025195A1

  公开（公告）日：2018-02-08

  The present invention is directed towards process for preparation of an optically pure (Sp)-Sofosbuvir of Formula-(I) and its intermediate namely (Sp)-isomer of isopropyl alanyl phosphoramidate of Formula (III) thereof.

  本发明涉及一种制备光学纯(Sp)-索非布韦（化学式(I)）及其中间体即异丙基丙氨基磷酰胺的(Sp)-异构体（化学式(III)）的方法。
• [EN] N-CONTAINING HETEROARYL DERIVATIVES AS JAK3 KINASE INHIBITORS<br/>[FR] DÉRIVÉS HÉTÉROARYLES CONTENANT N EN TANT QU'INHIBITEURS DE KINASE JAK3
  申请人：PALAU PHARMA SA

  公开号：WO2011051452A1

  公开（公告）日：2011-05-05

  N-containing heteroaryl derivatives of formula I or II, wherein the meanings for the various substituents are as disclosed in the description. These compounds are useful as JAK, particularly JAK3, kinase inhibitors.

  式I或II的含氮杂环衍生物，其中各取代基的含义如描述中所披露的。这些化合物可用作JAK，特别是JAK3激酶抑制剂。
• Preparation Method of Nucleoside Phosphoramidate Prodrugs and Intermediates Thereof
  申请人：BrightGene Bio-Medical Technology Co., Ltd.

  公开号：US20180237466A1

  公开（公告）日：2018-08-23

  Provided in the present disclosure are a novel preparation method of nucleoside phosphoramidate prodrugs and the intermediates thereof. In particular, the method is adopted to perform isomer separation on the reaction product from a first step and then perform a two-step chemical synthesis, so as to prepare a high-purity compound S p -1. The method has simple and convenient operation and low cost. The prepared resulting single isomer S p -1 has high purity, and the HPLC purity thereof is 95% or more, and further, 99% or more. The method is suitable for industrial production and can satisfy the need of clinical study. Further, also provided in the present disclosure are a key intermediate phosphorus reagent for preparing the high-purity compound S p -1 and the preparation method thereof.

  本公开提供了一种新颖的核苷酸磷酰胺酯前药及其中间体的制备方法。具体而言，该方法被采用用于对第一步的反应产物进行异构体分离，然后进行两步化学合成，以制备高纯度化合物S p -1。该方法操作简单方便，成本低廉。制备得到的单一异构体S p -1具有高纯度，其HPLC纯度为95%或更高，进一步可达99%或更高。该方法适用于工业生产，并能满足临床研究的需求。此外，本公开还提供了用于制备高纯度化合物S p -1及其制备方法的关键中间体磷试剂。